Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
- Comments Off on Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
- Feb, 21, 2023
- Eddie Phanichkul
- Press Article
San Diego, February 21, 2023 (GLOBE NEWSWIRE) – Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today announced initiation of enrollment of patients with cerebral amyloid angiopathy (CAA), an age-associated disease in which a protein called amyloid beta (Aβ) builds up […]
Read MoreAmydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study Of A Retinal Tracer For Parkinson’s Disease
- Comments Off on Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study Of A Retinal Tracer For Parkinson’s Disease
- Oct, 27, 2022
- Amydis
- Press Article
San Diego, October 27, 2022 (GLOBE NEWSWIRE) – Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today announced it has been awarded a third grant for $1.5M from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This grant will support the first-in-human study of […]
Read MoreAmydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
- Comments Off on Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
- Sep, 22, 2022
- Amydis
- Press Article
San Diego, September 22, 2022 (GLOBE NEWSWIRE) – Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced dosing of the first patients in the company’s Phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of […]
Read MoreAmydis Receives NIH Grant Award to Develop a Novel TDP43 Retinal Tracer in Patients with ALS and FTD
- Comments Off on Amydis Receives NIH Grant Award to Develop a Novel TDP43 Retinal Tracer in Patients with ALS and FTD
- Aug, 19, 2022
- Amydis
- Press Article
San Diego, August 18, 2022 (GLOBE NEWSWIRE) – Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant supports the […]
Read MoreAmydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
- Comments Off on Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
- Mar, 29, 2022
- Amydis
- Press Article
San Diego, CA, March 29, 2022: Amydis Inc., a healthcare company developing a new class of molecular retinal diagnostics and digital biomarkers to accelerate the early detection and monitoring of neurodegenerative diseases, today announced the appointment of internationally recognized clinician scientist, Robert N. Weinreb M.D. as the First Chair to the Scientific Advisory Board of […]
Read MoreAmydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
- No Comments
- Dec, 06, 2021
- Amydis
- Press Article
San Diego, December 6, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a biotechnology company developing novel ocular contrast agents (“tracers”) targeting CNS biomarkers in the eye, today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plans for a small-molecule tracer to detect […]
Read MoreAmydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy
- No Comments
- Oct, 11, 2021
- Amydis
- Press Article
San Diego, October 11, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a grant award of $3 million from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). […]
Read MoreAmydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and other Tauopathies
- No Comments
- Sep, 02, 2021
- Amydis
- Press Article
San Diego, September 2, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant will support […]
Read MoreAmydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
- No Comments
- Jun, 28, 2021
- Amydis
- Press Article
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced an award of a $3 million grant from the National Institute of Aging (NIA) at National Institutes of Health (NIH). The two-year Commercialization […]
Read MoreAmydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
- No Comments
- Apr, 26, 2021
- Amydis
- Press Article
San Diego, April 26, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases in the eye, today announced completion of pre-IND (Investigational New Drug) interaction with the U.S. Food and Drug Administration (FDA) regarding the current development plan for a […]
Read MoreLatest Releases
- Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
- Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study Of A Retinal Tracer For Parkinson’s Disease
- Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease
- Amydis Receives NIH Grant Award to Develop a Novel TDP43 Retinal Tracer in Patients with ALS and FTD
- Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
- Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS
- Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy
- Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and other Tauopathies
- Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
- Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies